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Abstract
Introduction: Anti-N-methyl-d-aspartic acid receptor (NMDAR) autoimmune encephalitis is one of the most challenging disorders
with both psychiatric and neurologic presentations. Approximately three-fourth of patients with anti-NMDA receptor encephalitis
(anti-NMDARE) first referred to psychiatrists.
Case Presentation: A 15-year-old female adolescent was admitted to a psychiatric hospital. She presented a history of behavior
changes, including aggression, the symptoms mimicking depression, and suicidal ideation, for one year. Then she showed more
severe disinhibited behaviors, stupor, and generalized tonic-colonic seizure, so she was hospitalized in a general hospital. After
neurological assessments, she was referred to a psychiatric hospital due to her uncontrollable aggressive behaviors in addition to
sleep disturbance, rapid mood swings, restlessness, stereotypic behaviors, fluctuating attention and concentration, misidentifica-
tion delusion, and perceptual changes. All lab tests and brain images were normal. Electroencephalograms showed generalized
sharp and slow waves. The autoimmune panel tests were requested. When anti-glutamate receptor antibody was finally reported in
her CSF, anti-NMDARE was finally diagnosed. Her symptoms improved by receiving five corticosteroid pulses.
Conclusions: In patients with first and acute psychotic symptoms, especially in young individuals with seizures, the possibility of
autoimmune disorders should be kept in mind, and complementary tests must be done for autoantibody detection.
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1. Introduction
Many studies have shown a complex relationship be-
tween psychotic symptoms and immune system disor-
ders, including autoimmune conditions (1). In some pa-
tients with first psychotic episodes, the anti-N-methyl-d-
aspartic acid receptor (NMDAR) antibody, as well as anti-
bodies against the potassium channel, have been found (1).
Anti-NMDAR autoimmune encephalitis is one of the
most challenging disorders with both psychiatric and
neurologic presentations. Distinguishing auto-antibodies
against neuronal receptors in neuropsychiatric disorders
would shed light on some aspects of psychotic disorders
like schizophrenia (2).
Approximately three-fourth of patients with anti-
NMDA receptor encephalitis (anti-NMDARE) are first
referred to psychiatrists (3, 4). The psychiatric symptoms
of this disorder include auditory and visual hallucinations,
delusions, bizarre and disinhibited behaviors, agitation,
and impaired consciousness. There are also other symp-
toms like motor disturbances (ranging from dyskinesia
to catatonia), seizures, and autonomic dysfunction. Mild
lymphocytic pleocytosis mildly increased CSF protein
concentration, and specific oligoclonal bands have been
shown in about 80% of patients (5).
There are two groups of differential diagnosis for psy-
chotic symptoms in children and adolescents, including
psychiatric disorders (schizophrenia, mood and anxiety
disorders, attention-deficit/hyperactivity disorder, post-
traumatic states, autism spectrum disorders, etc.) and
other medical conditions or organic brain psychosis.
Other medical conditions associated with psychosis are
infections (Creutzfeldt-Jakob disease, herpes encephalitis,
human immunodeficiency virus infection, etc.), metabolic
disturbances (adrenocortical insufficiency, Cushing’s dis-
ease, hypercalcemia, hypocalcemia, etc.), neurologic con-
ditions (cerebral neoplasms, cerebrovascular diseases, en-
cephalitis, etc.), certain genetic syndromes (fragile X syn-
drome, Klinefelter’s syndrome, metachromic leukodys-
trophy, etc.), and vitamin deficiencies (folate deficiency,
niacin deficiency, vitamin B12 deficiency, etc.) (6).
Because of various demonstrations of this serious but
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treatable disorder, its diagnosis may be difficult. The
golden time for diagnosis is the most important point
which must be noticed. On the other hand, a total lack of
specific guidelines, not only for diagnosis but also for treat-
ment, makes the situation more complicated.
In this case report, we presented a teenage girl with
anti-NMDAR encephalitis, who manifested with depres-
sion, suicidal ideation, and cognitive impairment leading
to poor school performance during the past one year. Be-
cause of these early symptoms, she was only treated for de-
pression. Her symptoms followed by behavioral changes,
acute psychosis, and eventually neurological symptoms,
but again, due to the lack of clinical suspicion, the correct
diagnosis was not made. The patient was hospitalized in a
psychiatric hospital after normal primary neurological as-
sessments and normal CSF tests. Finally, due to acute psy-
chosis symptoms and the presence of seizures, neurologi-
cal counseling was performed. This case is invaluable as it
reminds us of the importance of having clinical suspicion
for the correct diagnosis and timely treatment of this dis-
order.
2. Case Presentation
A 15-year-old single female adolescent who was a stu-
dent of the ninth grade, living in Tehran, was admitted to a
psychiatric hospital with changes in behaviors, aggressive
outbursts, impaired attention, suicidal ideas, depressive
mood, lethargy, and anorexia, for the past one whole year.
During this time, her performance at school was becoming
impaired, and her interpersonal relationships were get-
ting shaky.
She was hopeless, and therefore, she was referred to a
psychiatrist. Selective serotonin reuptake inhibitor (SSRI)
was prescribed for her depressive symptoms, but not only
did the symptoms not improve, but they also exaggerated
day by day. No other psychopathology was found, and
she had no history of any manic symptoms so far. There
were no signs of other medical illnesses or histories of sub-
stance and alcohol abuse. Her physical and psychological
development was normal, and her family history showed
diabetes and Hashimoto’s hypothyroidism.
On 23th March 2017, she suddenly showed disinhibited
behaviors like wearing inappropriate clothes or shoplift-
ing, but they lasted a short time, and she was not visited
by her medical doctor during this period.
On 8th April 2017, stupor and generalized tonic-colonic
(GTC) seizures appeared. Therefore she was hospitalized
at the emergency department of a general hospital. The
symptoms were controlled by intravenous diazepam, and
she was discharged after a couple of hours. She showed
no signs of fever or infections and did not report any head
trauma. Disinhibited behaviors and irrelevant speaking
before and after the seizures were reported by her fam-
ily, which were assumed as seizures auras. After an ar-
gument on the next day at home, GTC seizures occurred
two times, and she was immediately transferred to the
hospital. Seizures again occurred on two additional oc-
casions, and she showed fluctuations in the conscious-
ness level and disinhibited behaviors (e.g., swearing dur-
ing medical interview, knocking herself to the window to
jump out, and incoherent speech). Except for deep tendon
reflexes, which were symmetrically reduced (2+), other
neurological examinations, including cranial nerve tests,
movement tests, muscles’ tones, and gait and cerebellar
functional evaluations were normal. The brain computed
tomography (CT) and magnetic resonance imaging (MRI)
scans, cerebrospinal fluid (CSF) test, and other primary
lab tests (complete blood cell count, liver function tests,
electrolytes, urine toxicology analysis for substance abuse,
fasting blood sugar, and renal functional tests) were all
normal. In electroencephalograms (EEG), many artifacts
were reported due to poor cooperation; however, general-
ized sharp and slow waves were detected prominently on
the left side. After stabilization, she was discharged with
200 mg/three times a day of carbamazepine and Ca-D daily.
She was recommended to meet a neurologist and a psychi-
atrist the other day.
After the neurological assessments, on 29th April 2017,
she was referred to a psychiatric hospital due to her aggres-
sive and uncontrollable behaviors in addition to sleep dis-
turbance, rapid mood swings, restlessness, stereotypic be-
haviors, fluctuating attention and concentration, misiden-
tification delusion, and perceptual changes (i.e., the color
of everywhere was changed to blue). In the mental state
examination, the recent and remote memories, the work-
ing memory, four-digit forward and backward tests, gen-
eral knowledge, concentration, calculation, and time ori-
entation were impaired. She was irritable and cursing sud-
denly during the interviews.
During the first hospitalization, primary differential
diagnoses were bipolar mood disorder with psychotic fea-
tures and substance-induced psychotic disorder. As there
was a history of recent seizures without any report of sub-
stance abuse in a young girl with first-episode psychosis,
new consultation with a neurologist was suggested to rule
out neurological conditions such as encephalitis.
All laboratory tests (complete blood cell count, liver
functional tests, electrolytes, urine toxicology for sub-
stances, fasting blood sugar, kidney tests, thyroid function
tests, viral markers, paraneoplastic antigens, lupus anti-
coagulants, and rheumatologic tests) were normal, and
the urine toxicology test was negative for any substance.
Generalized slowing and generalized epileptic form dis-
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charges were reported in EEG while agitation and suici-
dal ideas were prominent in her mental state examination.
Brain MRI, with and without contrast, was normal. Chest,
abdominal, and pelvic CT scans were normal, and tumor
markers were negative.
Then autoimmune panel tests were requested while
agitation and confusion were making the patient out of
control.
Carbamazepine (400 mg) two times a day, quetiapine
(100 mg) two times a day, Na-valproate (500 mg) two times
a day, and folic acid and Ca-D supplements daily were pre-
scribed, but she did not show any clinical improvement
and gradually became more agitated.
Finally, anti-glutamate receptor antibody was reported
in her CSF, and anti-NMDA receptor encephalitis was finally
diagnosed.
She received five corticosteroid pulses (methylpred-
nisolone 500 mg) in five days. Carbamazepine and que-
tiapine continued. Her symptoms decreased afterwards,
but memory impairments were still notable. After one
year of follow-up, her family and the patient reported
that her school performance and interpersonal relation-
ships were completely improved, and all the symptoms
disappeared. Moreover, seizures were controlled by carba-
mazepine, and her memory impairment also completely
recovered. Nowadays, her quetiapine is discontinued, and
carbamazepine dosage is decreased. She does not suffer
from any adverse effect for now. Figure 1 shows the com-
plete clinical timeline referring to this case.
3. Discussion
Several studies have shown that anti-NMDA receptor
encephalitis is ranked second among antibody-associated
encephalitis. Prevalent presentations are personality
changes, psychosis, and catatonia (7).
As an inotropic glutamate receptor, NMDA-R is ex-
pressed in the presynaptic area and has effects on synaptic
transmission, brain plasticity, and maturation (8). In anti-
NMDA-R encephalitis, because of autoantibodies against
NMDA receptor1 (NR1), the function of NMDA receptor de-
creases (9). Some studies have found a relationship be-
tween the hypo-functionality of NMDA-R and schizophre-
nia, which may explain psychotic symptoms in anti-NMDA-
R encephalitis (10).
Anti- NMDA-R encephalitis symptoms are classified
into different stages; a flu-like phase in 70% of patients
presenting with fever, headache, nausea, vomiting, diar-
rhea, or upper respiratory tract symptoms. The next stage
includes psychiatric symptoms such as anxiety, insom-
nia, mania, grandiosity delusions, hyper-religiosity, and
paranoia. This stage is followed by autonomic instabil-
ity, seizures, decreased responsiveness, and in some cases,
short-term memory impairments (11). In our case, due
to deficits in attention and some depression-like symp-
toms, the patient’s function was impaired at the school.
No flu-like symptoms were reported by the patient and
her family. After that, disinhibited behaviors and seizures
appeared and followed by psychosis, disorganized behav-
iors, mood swings, and insomnia. Her recent and remote
memories, working memory, concentration, and orienta-
tion were also impaired. Since the initial symptoms were
merely psychiatric without any physical sign, there was
not a high clinical suspicion for association with medical
conditions. After the occurrence of seizures, medical ex-
aminations were performed more precisely, all of which
were normal, which is one of the features of this disorder,
rendering it undiagnosed. The strength of our approach
was that, despite repeated neurological visits, we simply
did not accept that the problem was only psychiatric due
to acute symptoms and seizures and asked for more neu-
rological consults.
Nearly 40% of these cases are below 18 years old. Usu-
ally, the patients are hospitalized in psychiatric wards be-
cause of their psychotic symptoms, and in this phase, pri-
mary or secondary psychosis is not easily distinguishable.
Unfortunately, some evaluations like brain MRI (60%) and
routine CSF analysis, unless antibodies are investigated
(10%), are not diagnostic; however, EEG is usually abnormal
(12). These atypical early manifestations, the normality of
early tests and imaging, and the absence of clinical suspi-
cion are among the most important barriers for the diag-
nosis of the disorder. Therefore, patients may be treated
for a primary psychiatric disorder without fully respond-
ing to the treatments and visiting different psychiatrists
while the course of the disorder deteriorates. This was the
scenario that happened to our patient.
Just as the above explanation, our case’s brain MRI
scans, and CSF analysis were normal, but EEG had patho-
logic changes (i.e., generalized slowing and generalized
epileptiform discharges).
The first-line treatment of anti-NMDA-R encephalitis
is immunotherapy [corticosteroids, intravenous immune
globulin (IVIG), and plasma exchange], improving the
symptoms in 53% of the cases during one month. The
second-line therapy is immunosuppression (rituximab or
cyclophosphamide) (5). Differences in initial treatment
regimens, based on specialty, include an increased use of
plasma exchange by adult neurologists (27%) and ritux-
imab by pediatric rheumatologists (29%). Physicians in the
US also utilize the second-line treatment earlier than most
of their European peers (13). Antipsychotics can be used
for psychiatric symptoms, but their adverse effects like ex-
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Figure 1. The timeline of this case report
trapyramidal symptoms before the correct diagnosis may
complicate the clinical diagnosis. On the other hand, cor-
ticosteroids may induce psychosis (5). In our patient, we
obtained an adequate response with the first-line therapy.
Psychiatric symptoms are usually controlled by psy-
chotropic drugs, but there is a higher risk of side-effects
like neuroleptic malignant syndrome (NMS) in these pa-
tients (14). We used quetiapine in this case, which did not
result in any adverse effect.
There is not enough information about how long im-
munotherapy should last, so we discontinued corticos-
teroid therapy after the symptoms improved. She recov-
ered completely after one year.
In summary, in patients with first and acute psychotic
symptoms, especially in young patients with seizures, the
possibility of autoimmune disorders should be kept in
mind, and complementary tests must be done for detect-
ing possible autoantibodies in these patients.
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